Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Immunotherapy ; 5(7): 703-15, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23829622

ABSTRACT

AIM: Immunotherapy with anti-HER2 antibodies has shown promising results in patients with HER2-positive breast cancer. We have recently reported characterization of a mouse monoclonal antibody (mAb) against HER2, which binds to an epitope different from that recognized by trastuzumab and specifically inhibits proliferation of tumor cells overexpressing HER2. In the present study we report chimerization of this antibody. MATERIALS & METHODS: The immunoglobulin variable region heavy and light chain genes of 1T0 hybridoma cells were amplified and ligated to human γ-1 and κ constant region genes using splice overlap extension PCR. The chimeric antibody was subsequently expressed and characterized by ELISA, western blot and flow cytometry. RESULTS: The purified chimeric antibody specifically binds to recombinant HER2 and HER2-overexpressing tumor cells and inhibits proliferation of these cells. The binding affinity of the chimeric mAb was comparable with the parental mouse mAb. CONCLUSION: This chimeric anti-HER2 mAb is a potentially valuable tool for targeted immunotherapy.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Breast Neoplasms/therapy , Immunization, Passive/methods , Protein Engineering/methods , Receptor, ErbB-2/antagonists & inhibitors , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/therapeutic use , Animals , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/immunology , Breast Neoplasms/immunology , Cell Proliferation , Female , Humans , Hybridomas , Immunodominant Epitopes/immunology , Mice , Molecular Targeted Therapy , Receptor, ErbB-2/immunology , Recombinant Fusion Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...